277 related articles for article (PubMed ID: 21679126)
1. LRRK2 Parkinson's disease: from animal models to cellular mechanisms.
Lin CH; Tsai PI; Wu RM; Chien CT
Rev Neurosci; 2011; 22(4):411-8. PubMed ID: 21679126
[TBL] [Abstract][Full Text] [Related]
2. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
Drolet RE; Sanders JM; Kern JT
J Neurogenet; 2011 Dec; 25(4):140-51. PubMed ID: 22077787
[TBL] [Abstract][Full Text] [Related]
5. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
Lu YW; Tan EK
J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
[TBL] [Abstract][Full Text] [Related]
6. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
7. Mutations in LRRK2 as a cause of Parkinson's disease.
Giasson BI; Van Deerlin VM
Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 in Parkinson's disease: protein domains and functional insights.
Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
[TBL] [Abstract][Full Text] [Related]
9. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.
Biskup S; West AB
Biochim Biophys Acta; 2009 Jul; 1792(7):625-33. PubMed ID: 18973807
[TBL] [Abstract][Full Text] [Related]
10. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
Moore DJ
Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
[TBL] [Abstract][Full Text] [Related]
11. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
Greggio E
Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
[TBL] [Abstract][Full Text] [Related]
12. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.
Cookson MR
Nat Rev Neurosci; 2010 Dec; 11(12):791-7. PubMed ID: 21088684
[TBL] [Abstract][Full Text] [Related]
13. Mouse models for LRRK2 Parkinson's disease.
Xu Q; Shenoy S; Li C
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S186-9. PubMed ID: 22166430
[TBL] [Abstract][Full Text] [Related]
14. [Advance of the study on LRRK2 gene in Parkinson's disease].
Zhang Y; Chen S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
[TBL] [Abstract][Full Text] [Related]
15. Leucine-rich repeat kinase 2: relevance to Parkinson's disease.
Guo L; Wang W; Chen SG
Int J Biochem Cell Biol; 2006; 38(9):1469-75. PubMed ID: 16600664
[TBL] [Abstract][Full Text] [Related]
16. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
Daniëls V; Baekelandt V; Taymans JM
Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.
West AB; Moore DJ; Choi C; Andrabi SA; Li X; Dikeman D; Biskup S; Zhang Z; Lim KL; Dawson VL; Dawson TM
Hum Mol Genet; 2007 Jan; 16(2):223-32. PubMed ID: 17200152
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 signaling pathways: the key to unlocking neurodegeneration?
Berwick DC; Harvey K
Trends Cell Biol; 2011 May; 21(5):257-65. PubMed ID: 21306901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
